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Background: Swedish and Danish national biologics registers have
reported a possible increase in melanoma risk with TNF inhibitors. As
melanomas are uncommon, the association is difficult to evaluate in
other individual registers. We therefore planned a EULAR collaborative
project.
Methods: Patients with RA from 11 European biologics registers in 9
countries were included. Patients were followed prospectively from
start of a new biologic treatment until the occurrence of first invasive
histology-confirmed cutaneous melanoma, using an ever-exposed
approach. For the TNFi cohort, prior exposure to biologic drugs was
not permitted. Prior exposure to TNFi was allowed for other biologic
drugs. For each register, incidence rates and standardized incidence
ratios (SIR) of melanoma were calculated by using age-, sex- and
calendar year-specific rates from the general population of the
corresponding country as reference. Poisson regression models
were used to summarize the register-specific SIRs to overall SIR
estimates. Rates of melanoma in biologic exposed patients were
compared with those in biologic-naive patients enrolled in participating
registers by calculating incidence rate ratios (IRRs). Overall SIRs and
IRRs were calculated, taking the size of the registers into account.
Results: Overall, 114 291 patients were available for analysis: mean
age 58 years; 74% female. 287 developed a first invasive melanoma.
Background population rates varied due to differences in the incidence
by country, calendar years and differences in the age and sex
distribution of the corresponding RA cohorts (Table 1). The SIRs for
biologic naı¨ve patients were similar across the registers whereas there
was variation in SIRs between TNFi cohorts (Table 1). The overall IRRs
did not show a significantly increased melanoma risk for any of the
biologic therapies compared with biologic-naive patients.
Conclusion: This large European collaborative project of 11 registers
from 9 countries did not confirm an increased risk of melanoma
following exposure to TNFi, although an association cannot be
completely ruled out with these data.
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099 TABLE 1. Melanomas, standardized incidence ratios and incidence rate ratios in RA treatment cohorts
Person-years Population rate,
per 100 000
Observed Expected SIR (95% CI) IRR (95% CI)
Biologic naive Total 300011 48 160 144.3 1.1 (0.9, 1.4) Referent
ARTIS 222496 52 133 115.5 1.2 (1.0, 1.4) Referent (ARTIS)
BSRBR 22972 35 9 8.0 1.1 (0.5, 2.1) Referent (BSRBR)
DANBIO 27469 57 14 15.7 0.9 (0.5, 1.5) Referent (DANBIO)
RABBIT 9916 33 4 3.3 1.2 (0.3, 3.1) Referent (RABBIT)
TNF Total 242814 35 106 85.5 1.2 (1.0, 1.6) 1.1 (0.8, 1.6)
ARTIS 59166 44 39 26.0 1.5 (1.1, 2.1) 1.3 (0.9, 1.9)
BSRBR 90259 31 31 28.1 1.1 (0.8, 1.6) 1.0 (0.5, 2.3)
DANBIO 22972 49 18 11.3 1.6 (0.9, 2.5) 1.8 (0.8, 3.9)
RABBIT 23103 31 7 7.1 1.0 (0.4, 2.0) 0.8 (0.2, 3.8)
GISEA 16180 40 6 6.4 0.9 (0.3, 2.0)
SCQM 15605 26 3 4.1 0.7 (0.2, 2.2)
ATTRA 8441 22 1 1.8 0.6 (0.0, 3.0)
Rheuma.pt 7088 9 1 0.7 1.5 (0.0, 8.3)
Rituximab Total 29619 35 13 10.3 1.3 (0.6, 2.5) 1.1 (0.5, 2.9)
Tocilizumab Total 5798 33 5 1.9 2.7 (0.8, 8.4) 2.4 (0.6, 10.1)
Abatacept Total 4858 29 2 1.4 1.5 (0.1, 30.9) 1.3 (0.2, 7.6)
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